Drug Availability

Further to DrugAlert Volume 470, HPS Pharmacies wish to give notice that Pfizer Australia is continuing to experience a supply interruption for DBL™ Pethidine Hydrochloride Injection BP as follows:

DBL™ Pethidine Hydrochloride Injection BP
Pethidine Hydrochloride 100mg/2mL
ARTG 107387

DBL™ Pethidine Hydrochloride Injection BP
Pethidine Hydrochloride 50mg/1mL
ARTG 107386

Normal supplies of DBL™ Pethidine Hydrochloride 100mg/2mL and 50mg/1mL are now expected to resume by the end of December 2020.

An internationally registered brand of pethidine 50mg/1mL ampoules and pethidine 100mg/2mL ampoules has been approved for supply under Section 19A of the Therapeutic Goods Act 1989. Unfortunately, the 50mg/1mL presentation is now experiencing a short-term supply interruption that is expected to resolve by the end of February 2020. It is advised to consider alternatives to pethidine, where appropriate, during this time.

Please note that Section 19A alternatives are subject to a longer lead time and different pricing as they must be sourced internationally.

Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.

Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies, or Pfizer Australia on 1800 629 921.